Divya Madan

Ms. Divya Madan

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2022 in The Lancet Regional Health - Southeast Asia
Verified
Journal Article
Open access
SMSumit Malhotra
Sumit Malhotra
KMKalaivani Mani
Kalaivani Mani
RLRakesh Lodha
Rakesh Lodha
SBSameer Bakhshi
Sameer Bakhshi
VMVijay Prakash Mathur
Vijay Prakash Mathur
SPSabitri Pandit
Sabitri Pandit
Surge of SARS CoV-2 infections ascribed to omicron variant began in December 2021 in New Delhi. We determined the infection and reinfection density in a cohort of health care workers (HCWs) along with vaccine effectiveness (VE) against symptomatic infection within omicron transmission period (considered from December 01, 2021 to February 25, 2022. This is an observational study from the All India Institute of Medical Sciences, New Delhi. Data were collected telephonically. Person-time at risk was counted from November 30, 2021 till date of infection/ reinfection, or date of interview. Comparison of clinical features and severity was done with previous pandemic periods. VE was estimated using test-negative case-control design [matched pairs (for age and sex)]. Vaccination status was compared and adjusted odds ratios (OR) were computed by conditional logistic regression. VE was estimated as (1-adjusted OR)X100-. 11474 HCWs participated in this study. The mean age was 36⋅2 (±10⋅7) years. Complete vaccination with two doses were reported by 9522 (83%) HCWs [8394 (88%) Covaxin and 1072 Covishield (11%)]. The incidence density of all infections and reinfection during the omicron transmission period was 34⋅8 [95% Confidence Interval (CI): 33⋅5–36⋅2] and 45⋅6 [95% CI: 42⋅9–48⋅5] per 10000 person days respectively. The infection was milder as compared to previous periods. VE was 52⋅5% (95% CI: 3⋅9–76⋅5, p = 0⋅036) for those who were tested within 14–60 days of receiving second dose and beyond this period (61–180 days), modest effect was observed. Almost one-fifth of HCWs were infected with SARS CoV-2 during omicron transmission period, with predominant mild spectrum of COVID-19 disease. Waning effects of vaccine protection were noted with increase in time intervals since vaccination. None.

20 January 2025 in Journal of Leukocyte Biology
Verified
Journal Article
Closed access
ABAsha Bhardwaj
Asha Bhardwaj
LSLeena Sapra
Leena Sapra
DMDivya Madan
Divya Madan
VAVineet Ahuja
Vineet Ahuja
HSHanuman Prasad Sharma
Hanuman Prasad Sharma
RSRupesh K. Srivastava
Rupesh K. Srivastava
Osteoporosis is a skeletal condition characterized by the deterioration of bone tissue. The immune system plays a crucial role in maintaining bone homeostasis and combating the development of osteoporosis. Immunoporosis is the term used to describe the recent convergence of research on the immune system's role in osteoporosis. The gut harbors the largest component of the immune system, and there is growing evidence that intestinal immunity plays a vital role in regulating bone health. Gut-resident regulatory T cells are essential in inhibiting immune responses and preventing various inflammatory manifestations. Our findings show that gut-resident regulatory T cells are pivotal in the pathophysiology of postmenopausal osteoporosis. We investigated the potential of gut-resident regulatory T cells in regulating the development of bone cells in vitro. We observed that gut-resident regulatory T cells significantly enhance osteoblastogenesis with concomitant inhibition of osteoclastogenesis in a cell ratio–dependent manner. We further report that the deficiency of short-chain fatty acids in osteoporotic conditions substantially disrupts the composition of gut-resident regulatory T cells, leading to a loss of peripherally derived regulatory T cells and an expansion of thymus-derived regulatory T cells. Moreover, the administration of probiotics Lactobacillus rhamnosus (UBLR-58) and Bifidobacterium longum (UBBL-64) modulated the gut-resident regulatory T cells compartment in a short-chain fatty acid-dependent manner to mitigate inflammatory bone loss in postmenopausal osteoporosis. Notably, short-chain fatty acid–primed gut-resident regulatory T cells were found to be significantly more effective in inhibiting osteoclastogenesis compared with unprimed gut-resident regulatory T cells. Altogether our results, for the first time, highlight the crucial role of gut-resident regulatory T cells in the pathophysiology of postmenopausal osteoporosis, with potential clinical implications.

13 October 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
VAVineet Ahuja
Vineet Ahuja
NSNamrata Singh
Namrata Singh
DMDivya Madan
Divya Madan
MFMariyam Farooqui
Mariyam Farooqui
NSNeha Singh
Neha Singh
VAVineet Ahuja
Vineet Ahuja
The use of smartphone-based applications as a telenutrition tool could redefine the nutritional management of IBD. We developed and validated a digital health platform in the form of a smartphone application for the nutritional assessment of IBD patients. Our team of gastroenterologists and dieticians at the All-India Institute of Medical Sciences, New Delhi developed a smartphone application titled IBD NutriCare, which was made available in both Android and iOS interfaces in English and seven other Indian languages. The application includes >650 Indian recipes and provides subjective global assessment and IBD clinical activity scores in a patient-friendly manner. The utility of the smartphone app was validated in comparison with the traditional 24-h dietary recall method. A total of 49 IBD patients were enrolled in the study. The mean difference in energy intake between the two dietary assessment methods was −4.776 kJ (95% LOA, range −417.916–408.365 kJ). A total of 94% of patients found the smartphone application convenient and acceptable in comparison to the recall method for dietary assessment. Bland–Altman plots showed a good level of agreement for nutrients and food groups between the two methods. Telenutrition in the form of a smartphone application helps in real-time tracking of dietary details of IBD patients, thus making appropriate interventions and large-scale data acquisition feasible.

17 June 2024 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
PDF file
SMSandeep K Mundhra
Sandeep K Mundhra
DMDivya Madan
Divya Madan
RGRithvik Golla
Rithvik Golla
PSPabitra Sahu
Pabitra Sahu
SVSudheer Kumar Vuyyuru
Sudheer Kumar Vuyyuru
SKSaurabh Kedia
Saurabh Kedia
Introduction: Overall, 30–40% patients with acute severe ulcerative colitis [ASUC] fail intravenous [IV] steroids, requiring medical rescue therapy/colectomy. Low baseline albumin predicts steroid non-response, and exclusive enteral nutrition [EEN] has been shown to improve steroid response and albumin levels. Albumin infusion, due to its anti-inflammatory and antioxidant properties, might further improve steroid response in ASUC, which was evaluated in the present study. Methods: In this open-label, randomised, controlled trial, patients with ASUC were randomised in 1:1 ratio to either albumin + standard of care [SOC] + EEN [Albumin arm] or SOC + EEN [SOC arm], over January 2021–February 2023. Both arms received 5 days of EEN with 400 mg IV hydrocortisone/day. Patients in the Albumin arm were administered 5 days of 20% weight/volume [w/v] intravenous albumin [100 ml]. Primary outcome was first, steroid failure [need for rescue medical therapy or colectomy] and second, proportion of patients with adverse events. Results: In all, 61 patients [albumin: 30, SOC: 31][mean age 31.6 ± 0.4 years, male 57.4%], were included. Baseline characteristics were comparable. There was no difference in steroid failure between Albumin and SOC arms (10/30 [33.33%] vs 13/31[41.94%], p = 0.49). No adverse events were reported with albumin infusions. Colectomy rate [10% vs 9.68%, p = 1], response to salvage medical therapy [88.89% vs 76.92%, p = 0.62] and median [interquartile range] duration of hospitalisation [10.5 [7-16] vs 10 [7-20], p = 0.43] were also comparable. The long-term composite outcome of colectomy and re-admission rates was numerically higher in the Albumin than the SOC arm [37.04% vs 17.86%, p > 0.05], although this did not reach statistical significance. Conclusion: There was no benefit of intravenous albumin infusion as an adjunct to IV steroids and EEN in patients with ASUC.

12 October 2023 in Journal of Clinical and Experimental Hepatology
Verified
Journal Article
Closed access
VAVineet Ahuja
Vineet Ahuja
SVSudheer Kumar Vuyyuru
Sudheer Kumar Vuyyuru
BKBhaskar Kante
Bhaskar Kante
PKPeeyush Kumar
Peeyush Kumar
MFMariyam Farooqui
Mariyam Farooqui
VAVineet Ahuja
Vineet Ahuja

9 October 2026 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
UAUmang Arora
Umang Arora
MVMahak Verma
Mahak Verma
DMDivya Madan
Divya Madan
MSMukesh Singh
Mukesh Singh
DKDevasenathipathy Kandasamy
Devasenathipathy Kandasamy
VAVineet Ahuja
Vineet Ahuja
Background: One-third of patients with acute severe ulcerative colitis (ASUC) fail intravenous corticosteroids. We evaluated whether adding tofacitinib to corticosteroids reduces treatment failure in ASUC. Methods: In this single-center, double-blind, placebo-controlled trial, adults with ASUC were randomized 1:1 to tofacitinib (10 mg three times daily for 3 days, then twice daily) or placebo for 5 days alongside corticosteroids. Primary outcome was treatment failure at day 6 (<3-point Lichtiger reduction or total score ≥10, or colectomy). Secondary outcomes were relapse (≥3-point rise with total ≥10), rescue therapy, and colectomy at 90 days. Modified intention-to-treat analysis was performed. (CTRI/2022/11/047186) Results: Of 62 randomized patients, 58 were analyzed: 33 in the tofacitinib arm and 25 in the placebo arm. The trial was terminated early because of slow recruitment and did not reach the planned sample size of 98. Day 6 treatment failure was numerically lower with tofacitinib in unadjusted analysis (24.2% vs 36.0%; RR 0.67, 95% CI 0.30-1.51; P = .33) and significantly lower after adjustment for baseline covariate imbalance (adjusted RR 0.47, 95% CI 0.24-0.93; P = .03). At 90 days, colectomy rates were similar (12.1% vs 12.0%; P = 1.0), but more tofacitinib-treated patients remained on assigned therapy (84.4% vs 54.2%) and rescue therapy was lower (HR 0.27, 95% CI 0.09-0.78; P = .01). Serious adverse events occurred in one versus three patients. No deaths occurred with tofacitinib versus two deaths with placebo. Conclusion: Dual therapy with tofacitinib and steroids in ASUC did not significantly reduce treatment failure at day 6, unless adjustment for baseline imbalance in serum albumin was taken into account. It reduced the need for rescue therapy over 90 days without affecting colectomy risk. Larger clinical trials are required to confirm these findings.